Liposomal formulation increases local delivery of amphotericin from bone cement: A pilot study infection

Brian Cunningham, Alex C. McLaren, Christine Pauken, Ryan McLemore

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Background: Amphotericin is a highly toxic hydrophobic antifungal. Delivery of amphotericin from antifungal-loaded bone cement (ALBC) is much lower than would be expected for an equivalent load of water-soluble antibacterials. Lipid formulations have been developed to decrease amphotericin toxicity. It is unknown how lipid formulations affect amphotericin release and compressive strength of amphotericin ALBC. Questions/purposes: We asked if amphotericin release from liposomal amphotericin ALBC (1) changed with amphotericin load; (2) differed from release from amphotericin deoxycholate ALBC; (3) was an active drug; and (4) if liposomal amphotericin affected the bone cement strength. Methods: Forty-five standardized test cylinders were fabricated from three formulations of ALBC: Simplex™ P bone cement with 200 mg liposomal amphotericin, 800 mg liposomal amphotericin, or 800 mg amphotericin deoxycholate per batch. For each ALBC formulation, cumulative released amphotericin was determined from five cylinders, and compressive strength was measured for 10 cylinders, five before elution and five after. Activity of released amphotericin was determined by growth inhibition assay. Results: Amphotericin release was greater for increased load of liposomal amphotericin: 770 μg for 800 mg versus 118 μg for 200 mg. Amphotericin release was greater from liposomal ALBC than from deoxycholate ALBC: 770 μg versus 23 μg over 7 days for 800 mg amphotericin. Released amphotericin was active. Compressive strength of liposomal ALBC is decreased, 67 MPa and 34 MPa by Day 7 in elution for the 200-mg and 800-mg formulations, respectively. Conclusions: Liposomal amphotericin has greater amphotericin release from ALBC than amphotericin deoxycholate. Compressive strength of liposomal amphotericin ALBC decreases to less than recommended for implant fixation. Local toxicity data are needed before liposomal amphotericin ALBC can be used clinically.

Original languageEnglish (US)
Pages (from-to)2671-2676
Number of pages6
JournalClinical orthopaedics and related research
Issue number10
StatePublished - Oct 2012

Bibliographical note

Funding Information:
One or more of the authors (ACM) received funding from the Astellas Pharmaceutical Corporation. Clinical Orthopaedics and Related Research neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA-approval status, of any drug or device prior to clinical use. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request. This work was performed at Arizona State University and Banner Good Samaritan Medical Center, Phoenix, AZ, USA.

Funding Information:
Acknowledgments We acknowledge Francis Calara BSE (mechanical testing) and Mary Martin PharmD at Banner Good Samaritan Medical Center for their contributions to this study and financial support from Banner Good Samaritan Medical Center and Astellas Pharma US, Inc.


Dive into the research topics of 'Liposomal formulation increases local delivery of amphotericin from bone cement: A pilot study infection'. Together they form a unique fingerprint.

Cite this